|
USRE30014E
(en)
*
|
1966-12-09 |
1979-05-29 |
Egyesult Gyogyazer-es Tapozergyar |
1-(3,4-Dimethoxy-phenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine
|
|
HU179018B
(en)
*
|
1978-10-19 |
1982-08-28 |
Gyogyszerkutato Intezet |
Process for producing new 5h-2,3-benzodiazepine derivatives
|
|
HU186760B
(en)
*
|
1981-03-12 |
1985-09-30 |
Gyogyszerkutato Intezet |
Process for preparing 3,4-dihydro-5h-2,3-aenzodiazepine derivatives
|
|
HU191698B
(en)
*
|
1984-07-27 |
1987-03-30 |
Gyogyszerkutato Intezet |
Process for producing new 1-aryl-5h-2beta-benzodiazepines
|
|
HU195788B
(en)
*
|
1986-05-21 |
1988-07-28 |
Gyogyszerkutato Intezet |
Process for producing 1-/hydroxy-stiryl/-5h-2,3-benzobiazepines and pharmaceutical compositions containing them
|
|
HUP9701284A3
(en)
*
|
1997-07-24 |
2005-11-28 |
Egyt Gyogyszervegyeszeti Gyar |
Use of 2,3-benzodiazepine derivatives for producing pharmaceutical compositions for treating and prophylacting illnesses and conditions connected with the endogene opioide system
|
|
ATE269705T1
(de)
*
|
1998-10-27 |
2004-07-15 |
Vela Pharmaceuticals Inc |
Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
|
|
US6080736A
(en)
*
|
1999-10-27 |
2000-06-27 |
Janus Pharmaceuticals, Inc. |
Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
|
|
FR2824065A1
(fr)
*
|
2001-04-26 |
2002-10-31 |
Neuro3D |
Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
|
|
US6649607B2
(en)
*
|
2001-05-18 |
2003-11-18 |
Vela Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing convulsions or seizures
|
|
US6638928B1
(en)
|
2002-12-03 |
2003-10-28 |
Vela Pharmaceuticals, Inc. |
Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
|
|
US7022700B2
(en)
*
|
2002-12-03 |
2006-04-04 |
Vela Pharmaceuticals, Inc. |
Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
|
|
US20040152695A1
(en)
*
|
2002-12-03 |
2004-08-05 |
Vela Pharmaceuticals, Inc. |
Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof
|
|
CA2508542A1
(en)
*
|
2002-12-03 |
2004-06-17 |
Vela Pharmaceuticals, Inc. |
Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
|
|
US6864251B2
(en)
*
|
2002-12-03 |
2005-03-08 |
Vela Pharmaceuticals, Inc. |
Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
|
|
US20040224943A1
(en)
*
|
2003-02-19 |
2004-11-11 |
Leventer Steven M. |
Method of lowering body temperature with (R) - 2,3-benzodiazepines
|
|
US20040162284A1
(en)
*
|
2003-02-19 |
2004-08-19 |
Harris Herbert W. |
Method of lowering body temperature with (S) tofisopam
|
|
CA2525273C
(en)
*
|
2003-05-16 |
2012-04-17 |
Vela Pharmaceuticals, Inc. |
Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
|
|
US20070021412A1
(en)
*
|
2003-05-16 |
2007-01-25 |
Vela Pharmaceuticals, Inc. |
Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S) 2,3-benzodiazepine
|
|
US20050288277A1
(en)
*
|
2004-06-25 |
2005-12-29 |
Kucharik Robert F |
Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S)-2,3-benzodiazepine
|
|
US20040254173A1
(en)
*
|
2003-06-13 |
2004-12-16 |
Leventer Steven M. |
Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines
|
|
FR2870539B1
(fr)
*
|
2004-05-19 |
2006-08-04 |
Greenpharma Sa Sa |
Nouvelles methodes et medicaments
|
|
US7541355B2
(en)
*
|
2005-05-23 |
2009-06-02 |
Vela Acquisition Corporation |
Conversion process for 2,3-benzodiazepine enantiomers
|
|
CN107915688A
(zh)
*
|
2016-10-09 |
2018-04-17 |
北京阜康仁生物制药科技有限公司 |
一种托非索泮的合成工艺改进方法
|